Romosozumab en la vida real en Castilla-La Mancha: ¿cumple las expectativas en la osteoporosis grave?

Estudio multicéntrico y observacional en mujeres posmenopáusicas con osteoporosis grave tratadas con romosozumab en hospitales de Castilla-La Mancha. Se evaluaron densidad mineral ósea (DMO), marcadores de remodelado óseo, fracturas y efectos adversos. Tras 12 meses, se observó una mejoría significativa en la DMO (columna lumbar, cadera total y cuello femoral) y reducción del riesgo de fractura (índice FRAX). No hubo cambios relevantes en marcadores óseos. El tratamiento mostró buena tolerancia, sin eventos cardiovasculares mayores y baja incidencia de fracturas. Romosozumab confirma eficacia y seguridad en práctica clínica real, especialmente en pacientes con baja DMO inicial y alto riesgo de fractura.

This multicenter, multidisciplinary, retrospective observational study included postmenopausal women with severe osteoporosis and/or high fracture risk treated with romosozumab in hospitals across Castilla-La Mancha. Variables analyzed were bone mineral density (BMD) by DXA (lumbar spine, femoral neck, and total hip), bone turnover markers, incidence of new fractures, and adverse events. After 12 months, a significant improvement in BMD was observed (lumbar spine T-score from -2.97 to -2.02; total hip from -2.46 to -2.24; femoral neck from -2.61 to -2.30) and a reduction in hip fracture risk (FRAX from 10.75% to 7.35%). Greater BMD gains were seen in patients with less prior treatment exposure. No significant changes were found in bone turnover markers. Safety profile was favorable, with no major cardiovascular events and low fracture incidence. Romosozumab confirms its efficacy and safety in real-world clinical practice, particularly in patients with low baseline BMD and high fracture risk.